DWS ESG Biotech TFC
DE000DWS2UA1
DWS ESG Biotech TFC/ DE000DWS2UA1 /
NAV2024-05-22 |
Chg.-0.3200 |
Type of yield |
Investment Focus |
Investment company |
173.1500EUR |
-0.18% |
reinvestment |
Equity
Worldwide
|
DWS Investment GmbH ▶ |
Investment strategy
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
To achieve this, the fund invests mainly in equities of international companies whose revenues or earnings, as reported in the most recent annual report or other suitable documents of the company, were generated primarily from the biotechnology sector, or whose expenditure was primarily on this sector. Equities of issuers from the health care sector may also be added. When selecting the suitable investments, environmental and social aspects as well as the principles of corporate governance ("ESG standards") are of key importance for the implementation of the fund"s sustainable investment strategy.
Investment goal
The fund is actively managed. The fund is not managed in reference to a benchmark. The fund promotes environmental and social characteristics and is subject to the disclosure requirements of a financial product in accordance with article 8(1) of Regulation (EU) 2019/2088 on sustainability-related disclosures in the financial services sector. More ESG information is available in the sales prospectus and on the DWS website. The objective of the investment policy is to achieve sustained capital appreciation that exceeds the benchmark (No benchmark).
Master data
Type of yield: |
reinvestment |
Funds Category: |
Equity |
Region: |
Worldwide |
Branch: |
Sector Biotechnology |
Benchmark: |
- |
Business year start: |
10-01 |
Last Distribution: |
- |
Depository bank: |
State Street Bank International GmbH |
Fund domicile: |
Germany |
Distribution permission: |
Austria, Germany |
Fund manager: |
Dr. Noushin Irani |
Fund volume: |
364.61 mill.
EUR
|
Launch date: |
2018-04-03 |
Investment focus: |
- |
Conditions
Issue surcharge: |
0.00% |
Max. Administration Fee: |
0.70% |
Minimum investment: |
0.00 EUR |
Deposit fees: |
- |
Redemption charge: |
0.00% |
Key Investor Information: |
Download (Print version) |
Investment company
Funds company: |
DWS Investment GmbH |
Address: |
Mainzer Landstraße 11-17, 60329, Frankfurt am Main |
Country: |
Germany |
Internet: |
www.dws.de
|
Assets
Stocks |
|
93.90% |
Money Market |
|
3.10% |
Cash |
|
3.00% |
Countries
United States of America |
|
82.10% |
Netherlands |
|
4.10% |
Denmark |
|
3.20% |
Germany |
|
1.80% |
United Kingdom |
|
0.70% |
Ireland |
|
0.60% |
Virgin Islands (British) |
|
0.50% |
Canada |
|
0.40% |
Sweden |
|
0.30% |
Switzerland |
|
0.20% |
Others |
|
6.10% |
Branches
Pharma/Biotechnology |
|
89.70% |
Pharma, production |
|
4.30% |
Others |
|
6.00% |